Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 5Active not recruiting 4Recruiting 3Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Melanoma 6Lung Neoplasms 6Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Glioblastoma 3Breast Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Sarcoma 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × Immunotherapy × Clear all
NCT07111104 2025-08-08

ARIS

Hopitaux Prives de Metz, Groupe UNEOS

Completed
350 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02035358 2022-04-06

Immunotherapy Study for Metastatic Renal Cell Cancer

Lumos Pharma

Phase 1 Completed
18 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡